补体成分5(C5)活性蛋白
Active Complement Component 5 (C5)
CPAMD4; C5a anaphylatoxin; C3 and PZP-like alpha-2-macroglobulin domain-containing protein 4
- 编号APB969Hu02
- 物种Homo sapiens (Human，人) 相同的名称，不同的物种。
- 缓冲液成份PBS, pH7.4, containing 0.01% SKL, 5% Trehalose.
- 性状冻干粉
- 纯度> 95%
- 等电点6.4
- 应用Cell culture; Activity Assays.
- 下载 英文说明书 中文说明书
- 规格 10µg50µg 200µg 1mg 5mg
- 价格 暂无报价 暂无报价 暂无报价 暂无报价 暂无报价
- 欲了解实际交易价格和更多情况，请与当地经销商联系!
-
产品包装(模拟)
-
产品包装(模拟)
-
Figure. SDS-PAGE
-
通过ISO 9001、ISO 13485质量体系认证
活性实验
Complement Component 5 (C5), which forms part of the later stages of the complement pathway, is cleaved into C5a and C5b. C5a is a chemotactic agent for neutrophils, while C5b forms part of the complement membrane attack complex. Coagulation Factor II (F2) has been identified as an interactor of C5, thus a functional binding ELISA assay was conducted to detect the interaction of recombinant human C5 and recombinant mouse F2. Briefly, C5 was diluted serially in PBS with 0.01% BSA (pH 7.4). Duplicate samples of 100 μl were then transferred to F2-coated microtiter wells and incubated for 1h at 37℃. Wells were washed with PBST and incubated for 1h with anti-C5 pAb, then aspirated and washed 3 times. After incubation with HRP labelled secondary antibody for 1h at 37℃, wells were aspirated and washed 5 times. With the addition of substrate solution, wells were incubated 15-25 minutes at 37℃. Finally, add 50 µL stop solution to the wells and read at 450/630 nm immediately. The binding activity of recombinant human C5 and recombinant mouse F2 was shown in Figure 1, the EC50 for this effect is 0.22 ug/mL.
用法
Reconstitute in 10mM PBS (pH7.4) to a concentration of 0.1-1.0 mg/mL. Do not vortex.
储存
避免反复冻融。2-8°C不超过一个月，-80°C不超过12个月。
稳定性
热稳定性以损失率显示。损失率是由加速降解试验决定，具体方法如下：在37°C孵育48小时，没有显著的降解或者沉淀产生。保质期内，在适当的条件下存储，损失率低于5%。
增值服务
相关产品
| 编号 | 适用物种：Homo sapiens (Human，人) | 应用(仅供研究使用，不用于临床诊断！) |
| RPB969Hu01 | 补体成分5(C5)重组蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| APB969Hu02 | 补体成分5(C5)活性蛋白 | Cell culture; Activity Assays. |
| RPB969Hu02 | 补体成分5(C5)重组蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| PAB969Hu01 | 补体成分5(C5)多克隆抗体 | WB; IHC; ICC; IP. |
| PAB969Hu02 | 补体成分5(C5)多克隆抗体 | WB; IHC; ICC; IP. |
| LAB969Hu71 | 补体成分5(C5)多克隆抗体(生物素标记) | WB; IHC; ICC. |
| MAB969Hu22 | 补体成分5(C5)单克隆抗体 | WB; IHC; ICC; IP. |
| SEB969Hu | 补体成分5(C5)检测试剂盒(酶联免疫吸附试验法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| LMB969Hu | 补体成分5(C5)等多因子检测试剂盒(流式荧光发光法) | FLIA Kit for Antigen Detection. |
参考文献
| 杂志 | 参考文献 |
| Journal of Clinical Immunology | Complement activation contributes to the injury and outcome of kidney in human anti-glomerular basement membrane disease. [PubMed: 22941511] |
| Journal of Neuroimmunology | Acute and prolonged complement activation in the central nervous system during herpes simplex encephalitis [Pubmed:27235358] |
| Cancer Letters | Complement C5a/C5aR pathway potentiates the pathogenesis Q5 of gastric cancer by down-regulating p21 expression [pubmed:29031586] |
| Proteomics Clinical Applications | iTRAQ‐Based Proteomic Analysis Reveals Protein Profile in Plasma from Children with Autism [Pubmed:29274201] |
| American journal of physiology. Endocrinology and metabolism | Impaired insulin signaling in the B10.D2-Hc H2 H2-T18/oSnJ mouse model of complement factor 5 (C5) deficiency [Pubmed: 31084499] |
| Proteomics Clinical Applications | Comparative proteomics analysis of serum proteins in gestational diabetes during early and middle stages of pregnancy [Pubmed: 31162828] |
| Aging | C5aR deficiency attenuates the breast cancer development via the p38/p21 axis [Pubmed: 32669478] |